Binding of influenza virus hemagglutinin to analogs of its cell-surface receptor, sialic acid: analysis by proton nuclear magnetic resonance spectroscopy and X-ray crystallography.Sauter, N.K., Hanson, J.E., Glick, G.D., Brown, J.H., Crowther, R.L., Park, S.J., Skehel, J.J., Wiley, D.C.
(1992) Biochemistry 31: 9609-9621
- PubMed: 1327122
- DOI: 10.1021/bi00155a013
- Structures With Same Primary Citation
- PubMed Abstract:
- Crystallographic Detection of a Second Ligand Binding Site in Influenza Virus Hemagglutinin
Sauter, N.K., Glick, G.D., Crowther, R.L., Park, S.-J., Eisen, M.B., Skehel, J.J., Knowles, J.R., Wiley, D.C.
(1992) Proc Natl Acad Sci U S A 89: 324
- Refinement of the Influenza Virus Hemagglutinin by Simulated Annealing
Weis, W.I., Brunger, A.T., Skehel, J.J., Wiley, D.C.
(1990) J Mol Biol 212: 737
- Structure of the Influenza Virus Hemagglutinin Complexed with its Receptor, Sialic Acid
Weis, W.I., Brown, J.H., Cusack, S., Paulson, J.C., Skehel, J.J., Wiley, D.C.
(1988) Nature 333: 426
- The Refinement of the Hemagglutinin Membrane Glycoprotein of Influenza Virus
Knossow, M., Lewis, M., Rees, D., Wilson, I.A., Skehel, J.J., Wiley, D.C.
(1986) Acta Crystallogr B 42: 627
- Three-Dimensional Structure of an Antigenic Mutant of the Influenza Virus Hemagglutinin
Knossow, M., Daniels, R.S., Douglas, A.R., Skehel, J.J., Wiley, D.C.
(1984) Nature 311: 678
- Structure of the Hemagglutinin Membrane Glycoprotein of Influenza Virus at 3 Angstroms Resolution
Wilson, I.A., Skehel, J.J., Wiley, D.C.
(1981) Nature 289: 366
- Structural Identification of the Antibody-Binding Sites of Hong Kong Influenza Hemagglutinin and Their Involvement in Antigenic Variation
Wiley, D.C., Wilson, I.A., Skehel, J.J.
(1981) Nature 289: 373
- Crystallization and X-Ray Diffraction Studies on the Hemagglutinin Glycoprotein from the Membrane of Influenza Virus
Wiley, D.C., Skehel, J.J.
(1977) J Mol Biol 112: 343
The interaction between influenza virus hemagglutinin and its cell-surface receptor, 5-N-acetylneuraminic acid (sialic acid), was probed by the synthesis of 12 sialic acid analogs, including derivatives at the 2-carboxylate, 5-acetamido, 4-, 7-, and ...
The interaction between influenza virus hemagglutinin and its cell-surface receptor, 5-N-acetylneuraminic acid (sialic acid), was probed by the synthesis of 12 sialic acid analogs, including derivatives at the 2-carboxylate, 5-acetamido, 4-, 7-, and 9-hydroxyl, and glycosidic positions. The equilibrium dissociation constants of these analogs were determined by nuclear magnetic resonance spectroscopy. Ligand modifications that reduced or abolished binding included the replacement of the 2-carboxylate with a carboxamide, the substitution of azido or N-benzyloxycarbonyl groups for the 5-acetamido group, and the replacement of the 9-hydroxyl with amino or O-acetyl moieties. Modifications having little effect on binding included the introduction of longer chains at the 4-hydroxyl position, the replacement of the acetamido methyl group with an ethyl group, and the removal of the 7-hydroxyl group. X-ray diffraction studies yielded 3 A resolution crystal structures of hemagglutinin in complex with four of the synthetic analogs [alpha-2-O-methyl-, 4-O-acetyl-alpha-2-O-methyl-, 9-amino-9-deoxy-alpha-2-O-methyl-, and alpha-2-O-(4'-benzylamidocarboxybutyl)-N-acetylneuraminic acid] and with the naturally occurring cell-surface saccharide (alpha 2-3)sialyllactose. The X-ray studies unambiguously establish the position and orientation of bound sialic acid, indicate the position of the lactose group of (alpha 2-3)sialyllactose, and suggest the location of an alpha-glycosidic chain (4'-benzylamidocarboxybutyl) that increases the binding affinity of sialic acid by a factor of about 3. Although the protein complexed with alpha-2-O-methylsialic acid contains the mutation Gly-135-->Arg near the ligand binding site, the mutation apparently does not affect the ligand's position. The X-ray studies allow us to interpret the binding affinities in terms of the crystallographic structure. The results suggest further experiments which could lead to the design of tight binding inhibitors of possible therapeutic value.
Department of Biochemistry and Molecular Biology, Howard Hughes Medical Institute, Cambridge, Massachusetts.